1. Lopez AD, Shibuya K, Rao C et al. Chronic Obstructive Lung Disease: current burden and future projections. Eur Respir J 2006; 27 (1): 188–207.
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997; 349 (9064): 1498–504.
3. Глобальная инициатива по хронической обструктивной болезни легких. Под. ред. А.Г.Чучалина. М.: Атмосфера, 2007.
4. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. Updated 2007 (www.goldcopd.com).
5. Хроническая обструктивная болезнь легких. Федеральная программа. Практическое руководство для врачей. 2-е изд. Под ред. А.Г.Чучалина. М., 2004.
6. Salpeter SR, Buckley NS, Salpeter EE. Meta-analysis: Anticholinergics, but not b-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med 2006; 21: 1011–9.
7. Milic-Emili J. Dynamic pulmonary hyperinflation and intrinsic PEEP: consequences and management in patients with chronic obstructive pulmonary disease. Rec Progress Med 1990; 81: 733–7.
8. O'Donnell DE, Fluge T, Gerken F et al. Effects of tiotropium on lung hyperinflation, dyspnоea and exercise tolerance in COPD. Eur Respir J 2004; 23: 86–94.
9. Tashkin DP, Celli B, Decramer M et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J 2008; 31: 742–50.